Antitumor effects of 3-bromoascochlorin on small cell lung cancer via inhibiting MAPK pathway

Zhenhua Zhang, Yidi Zhang, Chunju Yang, Qianyu Wang, Hong Wang, Yanting Zhang, Wenbin Deng, Yichu Nie, Yonghong Liu, Xiaowei Luo, Jie Huang, Junjian Wang

Research output: Contribution to journalArticlepeer-review


Small cell lung cancer (SCLC) was defined as a recalcitrant cancer, and novel therapies are urgently needed. Marine natural products (MNPs) may bring continuing hope for treatment of SCLC. In this study, 3-bromoascochlorin (BAS), an MNP isolated from the coral-derived fungus Acremonium sclerotigenum GXIMD 02501, was primarily screened out with antiproliferative activity towards SCLC cell lines. Then western blot analysis (WB) and flow cytometry were conducted, and we found BAS could induce the apoptosis of H446 and H69AR cells. Besides, BAS could suppress the invasion and migration of H446. In an SCLC xenograft mice model, BAS inhibited the growth of tumor without affecting the body weight of mice. Finally, the underlying mechanisms were preliminarily explored. According to the results of RNA-seq, reverse transcription-quantitative polymerase chain reaction, and WB, our results revealed that BAS exerted antitumor activity via inhibiting mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinases (ERK) pathway. Collectively, these results indicated that BAS can be used as a promising compound for the treatment of human SCLC.

Original languageEnglish (US)
Pages (from-to)2380-2390
Number of pages11
JournalCell Biology International
Issue number11
StatePublished - Nov 2021
Externally publishedYes


  • ascochlorin
  • FGFR1
  • MAPK/ERK pathway
  • marine natural product
  • small cell lung cancer

ASJC Scopus subject areas

  • Cell Biology


Dive into the research topics of 'Antitumor effects of 3-bromoascochlorin on small cell lung cancer via inhibiting MAPK pathway'. Together they form a unique fingerprint.

Cite this